Lab work is "high mix, low volume," like driving, making it hard to automate. Traditional automation is like a subway: efficient but inflexible. AI enables "autonomous" labs, akin to Waymo cars, that handle the vast variability of experiments, which constitutes 99% of lab work.

After a year of extensive experimentation, major pharmaceutical companies are now adopting AI at scale, marked by large-scale deals with AI tooling companies. This signals a market inflection point where pharma is moving beyond testing and is actively deploying AI across R&D and commercial functions after seeing demonstrable ROI.

The transformational power of AI in life sciences isn't just designing novel molecules, which fails to solve the costly clinical development bottleneck. Instead, agentic AI provides immense leverage to individual scientists, automating tasks like protocol writing and experiment analysis that previously took weeks.

The most significant opportunity for AI in healthcare lies not in optimizing existing software, but in automating 'net new' areas that once required human judgment. Functions like patient engagement, scheduling, and symptom triage are seeing explosive growth as AI steps into roles previously held only by staff.

AI delivers the most value when applied to mature, well-understood processes, not chaotic ones. Pharma's MLR (Medical, Legal, Regulatory) review is a prime candidate for AI disruption precisely because its established, structured nature provides the necessary guardrails and historical data for AI to be effective.

Large pharma companies are discovering that implementing AI to solve one part of the drug development workflow, like target discovery, creates new bottlenecks downstream. The subsequent, non-optimized stages become overwhelmed, highlighting the need for a holistic, fully choreographed approach to AI adoption across the entire R&D pipeline.

Contrary to fears of job replacement, AI's primary purpose in clinical trials is to automate low-value work like coordination and documentation. This frees up experts like CRAs and data reviewers to focus on high-value activities such as interpreting signals, managing risks, and making critical decisions, thereby amplifying their expertise.

While AI is a universal trend, its application is highly contextual. In drug discovery, it's used for complex, high-science tasks like protein folding. In the CDMO space, its value lies in streamlining less glamorous but critical functions like communication, paperwork, and process optimization.

Pharmaceutical giants are adopting AI not for moonshot "cure cancer" prompts, but to streamline critical, error-prone processes like compiling 10,000-page FDA documents. This mundane application prevents costly delays and accelerates time-to-market for multi-billion dollar drugs.